Recognition
Recognition

Celgene-Juno Deal Honored as “Alliance of the Year”

January 19, 2016
IN VIVO
Premier biopharma publication recognizes deal to help fight cancer and autoimmune diseases.

IN VIVO honored Celgene’s US$1 billion collaboration with Juno Therapeutics with its “Alliance of the Year” award for 2015. The transaction marks the highest ever upfront payment for a biopharma licensing deal, according to The Pink Sheet.

Latham & Watkins represented Juno Therapeutics in the agreement with a corporate team led by partners Judith Hasko and Robert Koenig.

Hasko, the firm’s Life Science Transactions global Chair, noted: “This groundbreaking and novel transaction was designed to enable both companies to discover and develop innovative cancer and immunology therapeutics."